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Antagonists, but not agonists, of the 5-HT3 receptor are useful therapeutic agents, and it is possible that partial agonists may also be potentially useful
in the clinic. Here we show that 5-fluorotryptamine (5-FT) is a partial agonist at both 5-HT3A and 5-HT3AB receptors with an Rmax (Imax / Imax5-HT) of
0.64 and 0.45 respectively. It is about 10 fold less potent than 5-HT: EC50=16 and 27 μM, andKi for displacement of [
3H]granisetron binding=0.8 and
1.8 μM for 5-HT3A and 5-HT3AB receptors respectively. We have also explored the potencies and efficacies of tryptamine and a range of 5-substituted
tryptamine derivatives. At 5-HT3A receptors tryptamine is a weak (Rmax=0.15), low affinity (EC50=113 μM; Ki=4.8 μM) partial agonist, while 5-
chlorotryptamine has a similar affinity to 5-FT (EC50=8.1 μM;Ki=2.7 μM) but is a very weak partial agonist (Rmax=0. 0037). These, and data from 5-
methyltryptamine and 5-methoxytryptamine, reveal the importance of size and electronegativity at this location for efficient channel opening.
© 2007 Published by Elsevier B.V. Open access under CC BY license.Keywords: Ligand-gated ion channel; Cys-loop receptor; Serotonin receptor; Partial agonist, Binding site; Homology model1. Introduction
The 5-HT3 receptor is a member of Cys-loop family of ligand-
gated ion channels, which also includes nicotinic acetylcholine,
GABA and glycine receptors (Reeves and Lummis, 2002). These
proteins are pentamers, and each subunit has a large extracellular
N-terminal domain, four transmembrane helices (M1–M4) and an
intracellular loop betweenM3 andM4. The binding site is located
at the interface of two adjacent subunits and is formed by the
convergence of three loops (A–C) from the principal subunit
and another three loops (D–F) from the complementary subunit
(Reeves and Lummis, 2002). Molecular details of the binding
pocket have been extrapolated from the structure of the acetyl-
choline binding protein, which is homologous to the extracellular
domain of Cys-loop receptors, and a range of amino acid residues
that are important for agonist and antagonist binding have been⁎ Corresponding author. Department of Biochemistry, Tennis Court Road,
Cambridge CB2 1AG, UK. Tel.: +44 1223 765950; fax: +44 1223 333345.
E-mail address: sl120@cam.ac.uk (S.C.R. Lummis).
0014-2999 © 2007 Published by Elsevier B.V.
doi:10.1016/j.ejphar.2007.11.014
Open access under CC BY license.identified (Reeves et al., 2003; Thompson et al., 2005). 5-HT3
receptors can function as homopentamers of 5-HT3A receptor
subunits, or as heteropentamers of 5-HT3A and 5-HT3B receptor
subunits (5-HT3AB receptors). The incorporation of B subunits
results in some changes in the biophysical characteristics of
the receptor, but has little effect on the pharmacological profile
(Brady et al., 2001; Davies et al., 1999; Dubin et al., 1999).
5-HT3 receptor antagonists have been suggested to be poten-
tially useful in treating inflammatory pain, anxiety, depression,
schizophrenia, and drug abuse (Greenshaw and Silverstone,
1997), and are currently in clinical practice for the treatment of
irritable bowel syndrome and emesis (Butler et al., 1988; Camilleri
et al., 2000; Sanger andNelson, 1989). It is therefore not surprising
that many 5-HT3 receptor antagonists have been developed. There
are, however, fewer 5-HT3 selective agonists. 2-methyl-5-HT and
mCBPG have beenwidely used, and some novel compounds have
been developed more recently such as benzoxazoles (Yoshida
et al., 2005) and pyrroloquinoxaline-related compounds (Cam-
piani et al., 1997). Here we explore the agonist properties of a
compound closely related to 5-HT, 5-fluorotryptamine (5-FT), at
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properties of 5-HT, mCBPG and tryptamine. We also explore
several other 5-substituted tryptamine derivatives.
2. Materials and methods
2.1. Materials
All cell culture reagents were obtained from Gibco BRL
(Paisley, U.K.), except foetal calf serum which was from
Labtech International (Ringmer, U.K.). [3H]granisetron
(63.5 Ci mmol−1) was from PerkinElmer (Boston, Massachu-
setts, USA). 5-FT, 5-chlorotryptamine (5-ClT), 5-methyltrypta-
mine (5-MeT), 5-methoxytryptamine (5-MeOT) and tryptamine
(Fig. 1) were from Sigma-Aldrich Co. Ltd. (Poole, Dorset, U.K.).
All other reagents were of the highest obtainable grade.
2.2. Cell culture and oocyte maintenance
Human embryonic kidney (HEK) 293 cells were maintained
in DMEM:F12 (Dulbecco's Modified Eagle Medium/Nutrient
Mix F12 (1:1)) with GlutaMAX™ containing 10% foetal calf
serum at 37 °C and 7% CO2 in a humidified atmosphere.
Xenopus laevis oocyte positive females were purchased from
NASCO (Fort Atkinson, Wisconsin, USA) and maintained
according to standard methods (Goldin, 1992).
Harvested stage V–VI Xenopus oocytes were washed in six
changes of ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2, 5 mM HEPES, pH 7.5), de-folliculated in
1.5 mg ml−1 collagenase Type 1A for approximately 2 h.
Enzyme treatment was terminated by washing in six changes of
ND96 and oocytes were stored in ND96 containing 2.5 mM
sodium pyruvate, 50 mM gentamicin and 0.7 mM theophylline.
2.3. Receptor expression
Mouse 5-HT3A (accession number: AY605711) or 5-HT3B
(accession number: NM_020274, kindly provided by Ewen
Kirkness) subunit cDNAs were cloned into pGEMHE for
oocyte expression (Liman et al., 1992). cRNA was in vitro
transcribed from linearised (NheI) plasmid cDNA templateFig. 1. Structures of the 5-HT3 receptor agonists used in this study.using the mMessage mMachine T7 kit (Ambion, Austin, Texas,
USA). Stage Vand VI oocytes were injected with 50 ng–100 ng
cRNA, and recorded from 1–4 days post-injection. For
expression in HEK 293 cells, 5-HT3 receptor subunit cDNAs
were cloned into pcDNA3.1 (Invitrogen Ltd., Paisley, UK.).
Mutagenesis reactions were performed using the Kunkel
method and confirmed by DNA sequencing. Cells were
transfected using calcium phosphate precipitation at 80–90%
confluency (Jordan et al., 1996). Following transfection cells
were incubated for 3–4 days before assay.
2.4. Radioligand binding
This was undertaken in HEK 293 cells which provide an
established and robust method of studying ligand binding.
Methods were as previously described (Lummis et al., 1993),
withminormodifications. Briefly, transfectedHEK 293 cells were
washed twice with phosphate buffered saline (PBS) at room
temperature and scraped into 1 ml of ice-cold HEPES buffer
(10 mM, pH 7.4) containing the following proteinase inhibitors
(PI): 1mMEDTA, 50μgml−1 soybean trypsin inhibitor, 50μg/ml
bacitracin and 0.1 mM phenylmethylsulphonyl fluoride. After
thawing, they were washed with HEPES buffer, resuspended, and
50 μg of cell membranes incubated in 0.5 ml HEPES buffer
containing 0.5 nM [3H]granisetron (a concentration approxi-
mately equivalent to theKd); non-specific bindingwas determined
using 10 μM quipazine. Competition binding was performed
using ligand concentrations from0.1μM–10mM.Reactionswere
incubated for at least 1 h at 4 °C and terminated by vacuum
filtration using a Brandel cell harvester onto GF/B filters pre-
soaked in 0.3% polyethyleneimine. Radioactivity was determined
by scintillation counting using a Beckman LS6000SC (Fullerton,
California, USA). Competition binding data were analyzed by
iterative curve fitting (GraphPad Prism v3.02, GraphPad Soft-
ware, San Diego, California, USA), according to the equation:
y ¼ Bmin þ Bmax  Bmin
1þ 10 L½ logIC50
where Bmin is the lowest total binding, Bmax is the maximum
specific binding at equilibrium, [L] is the concentration of
competing ligand and IC50 is the concentration of competing
ligand that blocks half of the specific bound radioligand.Ki values
were estimated from IC50 values using the Cheng–Prusoff
equation:
Ki ¼ IC501þ L½ =Kd
whereKi is the equilibrium dissociation constant for binding of
the unlabeled antagonist, [L] is the concentration of radioligand
andKd is the equilibrium dissociation constant of the radioligand.
2.5. Electrophysiology
Agonist-induced currents were recorded at 22–25 °C from
individual oocytes using the OpusXpress system (Molecular
Devices Axon Instruments, Union City, CA). 5-HT, m-
chlorophenylbiguanide (mCPBG), 5-FT and tryptamine
Fig. 2. Properties of 5-HT3A and 5-HT3AB receptors expressed inXenopus oocytes. Typical responses to maximal concentrations of 5-HT,mCPBG, 5-FTand tryptamine
in (A) 5-HT3A and (B) 5-HT3AB receptors; (C) Concentration–response curves in 5-HT3A receptors; (D) Relative efficacies (Rmax) of agonists compared to 5-HT.
Table 1
Functional parameters of 5-HT3A and 5-HT3AB receptors
pEC50 EC50 (μM) nH
A 5-HT 5.85±0.10 1.4 2.5±0.4
AB 5-HT 5.49± 0. 03 3.2 1.4±0.4
A 5-FT 4.80± 0. 05 16 2.4±0.5
AB 5-FT 4.57± 0. 08 27 1.4±0.3
A mCPBG 6.29± 0. 04 0.5 2.3±0.4
AB mCPBG 5.96± 0. 06 1.1 1.6±0.4
A tryptamine 3.91±.03 113 2.5± 0.5
AB tryptamine 4.22±.09 61 1.8± 0.5
Data=mean±SEM, n=4–6.
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Ca-free ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
5 mM HEPES, pH 7.5) and delivered to cells via the automated
perfusion system of the OpusXpress. Glass microelectrodes
were backfilled with 3 M KCl and had a resistance of ∼1 MΩ.
The holding potential was −60 mV. To determine EC50 values,
concentration–response data were fitted to the four-parameter
logistic equation, I= Imin+ (Imax−Imin) / (1+10 (log(EC50− [A])nH),
where Imax is the maximal response plateau, Imin is the minimum
response plateau, [A] is the log concentration of agonist and nH is
the Hill coefficient, using PRISM v4. 03 software (GraphPad, San
Diego, CA). Relative efficacies of the partial agonists are reported
as Rmax= Imaxdrug / Imax5-HT. One-way ANOVAs were per-
formed with Dunnett's post test to determine statistical signifi-
cance. Data are quoted asmean±SEM (n) unless otherwise stated.
3. Results
3.1. Effects of agonists on 5-HT3 receptor mediated currents
Application of 5-HT to Xenopus oocytes expressing 5-HT3A
or 5-HT3AB receptors produced concentration-dependent,rapidly activating, inward currents that desensitised over the
time-course of the application (Fig. 2). Plotting current
amplitude against a series of 5-HT concentrations revealed
EC50s of 1.4 μM and 3.2 μM with Hill slopes of 2.5 and 1.4
respectively (Table 1).
Application of 5-FT to Xenopus oocytes expressing 5-HT3A
or 5-HT3AB receptors also produced concentration-depen-
dent, rapidly activating, inward currents, with EC50s of 16 μM
and 27 μM and Hill slopes of 2.4 and 1.4 respectively. A
Table 4
Inhibition constants derived from [3H] granisetron binding to mutant 5-HT3A
receptors
5-HT (Ki, μM) 5-FT (Ki, μM)
WT 0.11±0.02 0.83±0.17
N128A 0.21±0.05 2.43 ± 0.47
T181A 0.19 ± 0.04 0.02 ± 0.34
E236A 0.20±0.05 1.62 ± 0.41
Data=mean+SEM, n=3–6.
Table 2
Relative efficacies (Rmax= Imax drug / Imax 5-HT)
5-FT mCPBG Tryptamine
A 0.64±0.03 0.74±0.07 0.15±0.06
AB 0.45±0.04 0.92±0.09 0.14±0.02
Data=mean±SEM, n=5–9.
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same maximal currents as those obtained from 5-HT applica-
tion in the same oocyte, indicating a partial agonist; 5-FT had a
Rmax (Imax drug / Imax 5-HT) of 0.64±0.03 for 5-HT3A receptors
and Rmax of 0.45±0.04 for 5-HT3AB receptors (Table 2).
Application of mCPBG produced concentration-dependent,
rapidly activating, inward currents, with EC50s of 0.5 μM and
1.1 μM and Hill slopes of 2.3 and 1.6 for 5-HT3A or 5-HT3AB
receptors, respectively. This compound had an Rmax of 0.74±
0.07 for 5-HT3A receptors and 0.92±0. 09 for 5-HT3AB
receptors.
Application of tryptamine produced concentration-depen-
dent, rapidly activating, inward currents, but here there was little
desensitisation over the time-course of the application (Fig. 2).
Plotting current amplitude against a series of tryptamine
concentrations revealed EC50s of 113 μM and 61 μM with
Hill slopes of 2.5 and 1.8 for 5-HT3A and 5-HT3AB receptors
respectively. Tryptamine had an Rmax of 0.15±0. 06 for 5-HT3A
receptors and an Rmax of 0.14±0. 03 for 5-HT3AB receptors.
5-ClT was a very weak partial agonist of 5-HT3A receptors,
with an Rmax of 0. 0037; the size of the responses precluded data
from 5-HT3AB receptors. Despite its low Rmax, 5- ClT had an
EC50 (8.1±0.3 μM, n=11) that was lower than that of 5-FT
(16 μM).
5-MeT was also a very weak partial agonist at 5-HT3A
receptors with an Rmax of 0. 0023. Dose response curves yielded
an EC50 of 60±3μM (n=3) indicating it was slightly more
potent than tryptamine (EC50=113 μM).
5-MeOT was unable to activate 5-HT3 receptors at
concentrations up to 10 mM.
3.2. [3H]granisetron binding studies
Saturation binding studies revealed no significant difference
in the affinity (Kd) of [
3H]granisetron between 5-HT3A and 5-
HT3AB receptors (0.42±0.15 and 0.62±0.21 nM respectively,Table 3
Inhibition constants derived from [3H] granisetron binding to 5-HT3A and 5-
HT3AB receptors
A (Ki, μM) AB (Ki, μM)
5-HT 0.11±0.02 0.11±0.03
mCPBG 0.010 ±0.003 0.012±0.004
5-FT 0.83±0.17 1.8±0.4
Tryptamine 4.8±0.9 15.5±3.5
5-Cl-tryptamine 2.7±0.7 3.1±1.1
5-Me-tryptamine 11. 0±0.9 7.7±1.1
5-MeO-tryptamine 34.9±3.0 21.7±2.1
Data=mean±SEM, n=3–6.n=3). Competition binding studies using [3H]granisetron
revealed displacement of specific binding in a concentration-
dependent manner by all the ligands. Kis (Table 3) revealed that
5-HT, mCPBG, 5FT and tryptamine did not substantially
distinguish between 5-HT3A and 5-HT3AB receptors.
[3H]granisetron competition studies using 5-ClT, 5-MeT and
5-MeOTon membranes from cells expressing 5-HT3A receptors
revealed 5-ClT had a similar Ki to 5-FT, which was ∼10 fold
more than the Ki for 5-HT. Values for tryptamine, 5-MeT and 5-
MeOT were ∼50, 100 and 300 fold greater than 5-HT
respectively (Table 3).
Competition radioligand binding studies on the mutant
receptors N128A, T181A and E236A, revealed no significant
changes in Ki values compared to WT receptors for either 5-FT
or 5-HT (Table 4). E129A and T179A mutant receptors had
either no specific radioligand binding, or levels were too low to
obtain accurate data as previously reported (Sullivan et al.,
2006).
4. Discussion
The data described here show that 5-FT is a partial agonist at
both 5-HT3A and 5-HT3AB receptors, with an Rmax close to 0.5
and an EC50 about 10 fold higher than 5-HT. Similarly,
tryptamine is a partial agonist at both types of receptor, as
previously reported for various native and recombinant 5-HT3
receptors, including those natively expressed in N1E-115 cells,
which may possess both 5-HT3A and 5-HT3B receptor subunits
(van Hooft and Vijverberg, 1996). Tryptamine has a lower
potency than both 5-HT and 5-FT (EC50 10–100 fold higher)
and a lower Rmax, indicating the importance of the group at the 5
position of 5-HT. Further studies on other 5-substituted
tryptamine derivatives confirm this hypothesis, and also reveal
the importance of size and electronegativity at this location for
efficient channel opening.
Subtle differences between 5-HT3A and 5-HT3AB receptors
have been reported by a number of authors, and were also
observed in the current study. Compared to the 5-HT3A receptor,
responses from 5-HT3AB receptors are smaller and desensitise
more rapidly; EC5O and Kd values differ by ∼2 fold and there is
an ∼2 fold decrease in the Hill slope of the dose response
curves. There is also a difference in the efficacy of mCPBG,
which acts as a partial agonist at 5-HT3A receptors, but a full
agonist at 5-HT3AB receptors. This indicates gating character-
istics of the two receptors are different, and indeed it has been
established that the channel conductance is greatly increased in
5-HT3AB receptors (Davies et al., 1999).
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differences in the affinities (EC50 and IC50s) of 5-HT3A and
5-HT3AB receptors for a range of 5-HT3 selective ligands
(Brady et al., 2001), and we observed a similar absence of
selectivity for 5-HT, mCPBG, 5-FT and tryptamine in this
study. These results are somewhat surprising, given that a recent
study has suggested that in the heterologously expressed 5-
HT3AB receptors the subunits are in the order BABBA (Barrera
et al., 2005), and, as agonist binding sites in Cys-loop receptors
are constituted from two adjacent subunits, these data imply that
binding interfaces would either be AB (most likely), BA or BB.Fig. 3. Alignment of 5-HT3A and 5-HT3B subunit sequences. Residues that have sim
binding site are underlined.Based on the sequence alignment (Fig. 3), one would expect
significant structural differences due to the different residues
that would contribute to AA compared to AB/BA or BB binding
sites. At present, we cannot explain why there are not larger
changes in pharmacological characteristics of the AB receptor.
The new data reveal some interesting features of the binding
pocket. Tryptamine is ∼100 fold less potent and much less
efficacious than 5-HT (Rmax=∼0.15), establishing the impor-
tance of the hydroxyl group. However 5-FT can significantly
compensate for the lack of a hydroxyl; it is only 10 fold less
potent than 5-HT and Rmax=∼0.5. In our model of the bindingilar chemical properties are shown in grey. The binding loops that constitute the
296 K.S. Bower et al. / European Journal of Pharmacology 580 (2008) 291–297pocket (Reeves et al., 2003), the hydroxyl of 5-HT is located in
a hydrophilic pocket constituted of Asn128, Glu129, Thr179,
Thr181 and Glu236, and it has the potential to hydrogen bond
with at least one of these residues (Fig. 4). Mutation of Asn128,
Thr181 and Glu236 to Ala results in no significant changes to
the 5-HT Ki, suggesting that Glu129 and Thr179 are the most
likely residues to contribute to hydrogen bonds. However as
alanine substitutions at these positions result in poor receptor
expression we cannot yet prove this hypothesis. 5-FT can be
located in a similar location to 5-HT, but we believe it is unlikely
that F also forms hydrogen bonds here. Fluorine is the most
electronegative element, and as such it is reluctant to donate a
lone pair of electrons to a hydrogen bond donor. As a result,
organic fluorine (fluorine bonded to a carbon) hardly ever
accepts a hydrogen bond (Dunitz, 2004). Even without a
hydrogen bond, however, it appears that an electronegative atom
is more favourable than no substituent at all at this location.
To further explore this region of the binding site, we
examined 5-ClT, 5-MeT and 5-MeOT in 5-HT3A receptors. 5-
ClT was of similar potency to 5-FT in the functional assays
(EC50=8 μM) but was much less effective in opening theFig. 4. 5-HT docked into a homology of the 5-HT3 receptor (Reeves et al., 2003).
A. The extracellular domains of two subunits of the 5-HT3 receptor showing the
location of the binding pocket (boxed) at their interface. B. Enlarged image of the
binding site showing the proximity of the hydroxyl group of 5-HT to the
hydrophilic residues Asn128, Glu129 Thr179, Thr181 and Glu236.channel (Rmax=0. 0037). 5-ClT and 5-FT bind to the receptor
with similar affinities (Kis are not significantly different),
demonstrating there is no relationship between Ki or EC50 and
Rmax Thus it appears that the atom at the 5 position of
tryptamine plays a critical role in the conformational changes
that result in channel opening. Since both 5-FT and 5-ClT
present a relatively electronegative atom at this position, we
propose that the increased steric size of Cl vs. F contributes to
decreased efficacy of 5-ClT. Sterics also rationalize the
inefficacy of 5-MeOT, which has an electronegative element
in the 5 position but is apparently too large. The data from 5-
MeT also support the hypothesis that size and polarity are
important; Me is a similar size to Cl, but is nonpolar, and 5-MeT
is less effective at opening the channel.
The data also show that for most agonists there is a direct
relationship between EC50 and Ki, with EC50s 13–50 fold
higher than Ki. This is expected, as Ki values are considered to
represent binding to a high affinity desensitised state. However,
for 5-ClT and 5-MeT, which have very low efficacy, EC50 is less
than 5 fold higher than Ki. This suggests that if agonist binding
does not result in significant channel opening (Rmax less than
0.01), then there may be no significant entry of receptors into
a high affinity state.
Partial agonists are increasingly being used to distinguish
between binding and gating events at Cys-loop receptors, and 5-
FT, with an Rmax of ∼0.5, will be a useful addition to this class
of compounds which includes the more usually used mCBPG
(Rmax=∼0.8) and 2-methyl-5-HT (Rmax=∼0.2). Partial ago-
nists are also potentially useful as therapeutic agents. The most
well-established role of 5-HT3 receptors is in regulating
gastrointestinal motility and the vomiting reflex, although
they may play a role in many other neuronal functions.
Currently, 5-HT3 receptor antagonists are used clinically as anti-
emetics, and to treat irritable bowel syndrome (Butler et al.,
1988; Camilleri et al., 2000; Sanger and Nelson, 1989).
However, there is some evidence that these compounds also
cause side effects in many patients, by inhibiting normal lower
bowel function (Talley, 1992). Thus there has been an increased
interest in 5- HT3 receptor partial agonists which might control
gastroenteric motility without completely blocking 5-HT3-
sensitized nerve function (Sato et al., 1997; Sato et al., 1998).
5-HT3 receptor agonists also have a potential therapeutic role as
they can modulate acetylcholine release in vivo (Consolo et al.,
1994), making these compounds of interest for the treatment of
neurodegenerative and neuropsychiatric disorders in which
cholinergic neurons are affected. Full 5-HT3 receptor agonists,
however, cause nausea and vomiting; thus partial agonists are
potentially more useful for therapeutic applications in this area.
Recently developed compounds, e.g those described by Yoshida
et al. (2005), are probably potentially more useful as
therapeutics than 5-FT, but a comparison of their actions
compared to 5-FT may clarify details of their mode(s) of action.
In conclusion we have shown that 5-FT is a partial agonist at
both homomeric 5-HT3A and heteromultimeric 5-HT3AB
receptors. The data have also revealed that the atom in the 5
position of 5-HT plays an important role both in receptor
binding and in subsequent channel gating.
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